Literature DB >> 11329788

[A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with angiotensin-II and administration of tegafur/uracil].

T Ishikawa1, S Sato, J Matsuzawa, Y Mita, S Matsui, K Tashiro, S Tashiro, H Matsuki.   

Abstract

Nontypical chemotherapy regimens exist for advanced pancreatic cancer. We herein report a 62-year-old man whose nonresectable pancreatic cancer was treated effectively with a new method of intra-arterial regional chemotherapy with angiotensin-II (AT-II). The patient was admitted to our hospital with obstructive jaundice and anorexia. He was diagnosed as having inoperable advanced pancreatic cancer with liver metastasis. Enteric-coated tegafur/uracil (400 mg) was administered for 3 weeks. Simultaneously, intraarterial infusion with 5-fluorouracil (500 mg) and infusion of methotrexate (100 mg) with 50 micrograms of AT-II was given every week. A catheter connected to a subcutaneously implanted port system was placed into the common hepatic artery. As a result of this treatment, the maximum diameter of the pancreatic tumor decreased from 3 cm to 2 cm on the CT-scan. Serum carbohydrate antigen 19-9 (CA19-9) decreased from 24,000 U/ml to 186 U/ml. Moreover, the performance status of patient also improved, and he was discharged from our hospital despite his terminal cancer. This regimen could well be effective in cases of advanced pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11329788

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

Review 1.  Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

Review 2.  Is it relevant that intra-arterial chemotherapy may be effective for advanced pancreatic cancer?

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.